Free tool
FAERS Monitor: Jevtana Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201023 or its brand name (Jevtana Kit, Cabazitaxel). Reports on generic versions are filed under their own applications.
Reports
3,517
Serious
0
0% of reports
Hospitalization
1,348
Death reported
705
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia250
- malignant neoplasm progression238
- fatigue210
- prostatic specific antigen increased202
- diarrhoea191
- disease progression187
- anaemia180
- neutropenia174
- pyrexia172
- drug ineffective162
- death155
- asthenia139
- dyspnoea138
- metastases to bone130
- haematuria125
Reports by year received
View as table
| Year | Reports |
|---|
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,642 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 250 | 22.6 | 20.1 | 5,141 |
| haematuriaSignal | 125 | 21.9 | 18.4 | 2,468 |
| malignant neoplasm progressionSignal | 238 | 13.9 | 12.3 | 2,850 |
| disease progressionSignal | 187 | 9.5 | 8.2 | 1,413 |
| neutropeniaSignal | 174 | 7.7 | 6.6 | 1,006 |
| anaemiaSignal | 180 | 5.6 | 4.9 | 690 |
| pyrexiaSignal | 172 | 3.0 | 2.6 | 227 |
| astheniaSignal | 139 | 2.2 | 1.9 | 93 |
| diarrhoea | 191 | 1.8 | 1.5 | 65 |
| fatigue | 210 | 1.6 | 1.4 | 50 |
| dyspnoea | 138 | 1.5 | 1.2 | 20 |
| death | 155 | 1.1 | 0.9 | 1 |
| drug ineffective | 162 | 0.7 | 0.6 | 16 |
| prostatic specific antigen increased | 202 | 0.0 | 0.0 | 1,203,083 |
| metastases to bone | 130 | 0.0 | 0.0 | 772,132 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.